NASDAQ:NK - Nantkwest Stock Price, Forecast & News

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Nantkwest Inc (NASDAQ:NK) announced its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.02. The biotechnology company earned $0.01 million during the quarter. Nantkwest had a negative return on equity of 44.91% and a negative net margin of 164,604.89%. View Nantkwest's Earnings History.

Nantkwest is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Nantkwest.

1 equities research analysts have issued 12 month price targets for Nantkwest's stock. Their forecasts range from $1.00 to $1.00. On average, they anticipate Nantkwest's share price to reach $1.00 in the next twelve months. This suggests that the stock has a possible downside of 78.7%. View Analyst Price Targets for Nantkwest.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for Nantkwest.

Media headlines about NK stock have trended very negative this week, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nantkwest earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Nantkwest.

Nantkwest saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 3,750,000 shares, an increase of 29.3% from the January 30th total of 2,900,000 shares. Based on an average daily volume of 1,980,000 shares, the days-to-cover ratio is currently 1.9 days. Approximately 41.0% of the shares of the stock are sold short. View Nantkwest's Current Options Chain.

Some companies that are related to Nantkwest include Alector (ALEC), Regenxbio (RGNX), Cortexyme (CRTX), SpringWorks Therapeutics (SWTX), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM), NanoString Technologies (NSTG), Editas Medicine (EDIT), Orchard Therapeutics (ORTX), I-Mab (BDTX), Twist Bioscience (TWST), BAVARIAN NORDIC/S (BVNRY), Krystal Biotech (KRYS), DBV TECHNOLOGIE/S (DBVT) and Mesoblast (MESO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Nantkwest investors own include Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Novavax (NVAX), Mallinckrodt (MNK), Fate Therapeutics (FATE), Immunomedics (IMMU), Opko Health (OPK), Selecta Biosciences (SELB) and Vodafone Group (VOD).

(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.

Nantkwest's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.66%), Geode Capital Management LLC (0.29%), Charles Schwab Investment Management Inc. (0.17%), Credit Suisse AG (0.13%), Laurion Capital Management LP (0.02%) and Oppenheimer & Co. Inc. (0.02%). Company insiders that own Nantkwest stock include John C Thomas and Steve Gorlin. View Institutional Ownership Trends for Nantkwest.

NK stock was sold by a variety of institutional investors in the last quarter, including Oppenheimer & Co. Inc., State Street Corp, UBS Group AG, Victory Capital Management Inc. and Victory Capital Management Inc.. View Insider Buying and Selling for Nantkwest.

NK stock was acquired by a variety of institutional investors in the last quarter, including Credit Suisse AG, Renaissance Technologies LLC, Charles Schwab Investment Management Inc., Geode Capital Management LLC, Laurion Capital Management LP, Alpine Global Management LLC and National Asset Management Inc.. View Insider Buying and Selling for Nantkwest.

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NK stock can currently be purchased for approximately $4.69.

Nantkwest has a market capitalization of $461.36 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,230,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Nantkwest employs 161 workers across the globe.View Additional Information About Nantkwest.

The official website for Nantkwest is http://www.nantkwest.com/.

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]